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PuBACKGROUND Antithrombotic therapy for acute myocardial infarction (MI) with atrial ﬁbrillation (AF) among higher
risk older patients treated with percutaneous coronary intervention (PCI) remains unclear.
OBJECTIVES This study sought to determine appropriate antithrombotic therapy for acute MI patients with AF treated
with PCI.
METHODS We examined 4,959 patients$65 years of age with acute MI and AF who underwent coronary stenting (Acute
Coronary Treatment and Intervention Outcomes Network Registry–Get With the Guidelines). The primary effectiveness
outcomewas 2-yearmajor adverse cardiac events (MACE) comprising death, readmission forMI, or stroke; the primary safety
outcome was bleeding readmission. Outcomes with dual antiplatelet therapy (DAPT) or triple therapy (DAPT plus warfarin)
were compared using Cox proportional hazard modeling with inverse probability-weighted propensity adjustment.
RESULTS Among 4,959 patients, 27.6% (n ¼ 1,370) were discharged on triple therapy. Relative to DAPT, patients on
triple therapy had a similar risk of MACE (adjusted hazard ratio [HR]: 0.99 [95% conﬁdence interval (CI): 0.86 to 1.16])
but signiﬁcantly greater risk of bleeding requiring hospitalization (adjusted HR: 1.61 [95% CI: 1.31 to 1.97]) and greater
risk of intracranial hemorrhage (adjusted HR: 2.04 [95% CI: 1.25 to 3.34]). Of 1,591 Medicare Part D patients, 90-day
post-discharge warfarin persistence among patients discharged on warfarin was 93.2% (n ¼ 412). Results of 90-day
landmark analyses comparing triple therapy versus DAPT in patients persistently on warfarin versus those not discharged
on warfarin who had not ﬁlled a warfarin prescription were similar to our primary ﬁndings.
CONCLUSIONS Approximately 1 in 4 older AF patients undergoing PCI for MI were discharged on triple therapy. Those
receiving triple therapy versus DAPT had higher rates of major bleeding without a measurable difference in composite MI,
death, or stroke. (J Am Coll Cardiol 2015;66:616–27) © 2015 by the American College of Cardiology Foundation.m the *Duke Clinical Research Institute, Duke University, Durham, North Carolina; yUniversity of Texas Southwestern Medical
nter, Dallas, Texas; zDepartment of Cardiology, Copenhagen University Hospital Gentofte, Copenhagen, Denmark; xBrigham
d Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts; and the kNorth Shore
iversity Health System, Evanston, Illinois. This work was supported by grant number U19HS021092 from the Agency for
althcare Research and Quality. The ACTION Registry–GWTG is an initiative of the American College of Cardiology Foundation
d the American Heart Association, with partnering support from the Society of Chest Pain Centers, the American College of
ergency Physicians, and the Society of Hospital Medicine. This research was supported by the American College of Cardiology
undation’s National Cardiovascular Data Registry. The views expressed in this paper represent those of the authors and do not
cessarily represent the ofﬁcial views of the National Cardiovascular Data Registry or its associated professional societies
ntiﬁed at www.ncdr.com. Dr. Hess has received research grant support from Gilead Sciences, Inc. Dr. Peterson has received
titutional grant support from the American College of Cardiology, the American Heart Association, Eli Lilly, and Janssen; and
nsulting fees (including Continuing Medical Education) from Merck & Co., Boehringer Ingelheim, Genentech, Janssen, and
noﬁ. Dr. Bhatt has served on the advisory board for Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and
gado Biosciences; is on the board of directors for Boston VA Research Institute and Society of Cardiovascular Patient Care; is
air for the American Heart Association Get With The Guidelines Steering Committee; is on the data monitoring committees for,
ke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute has
eived honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir
blications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard
AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
CABG = coronary artery bypass
grafting
CHADS2 = congestive heart
failure, hypertension, age ‡75
years, diabetes, prior stroke/
transient ischemic attack
CI = conﬁdence interval
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617S election of the optimal antithrombotic regimenfor patients with acute myocardial infarction(MI) who have concomitant atrial ﬁbrillation
(AF) and are treated with percutaneous coronary
intervention (PCI) presents a therapeutic challenge.
Current guidelines for the management of AF recom-
mend anticoagulation for thromboembolic prophy-
laxis in AF patients who are at average or higher
risk for stroke but not at prohibitive risk for bleeding
(1). Guidelines for the management of acute MI andSEE PAGE 628
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
HR = hazard ratio
MACE = major adverse cardiac
event(s)
MI = myocardial infarction
NSTEMI = non–ST-segment
elevation myocardial infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarctionPCI patients recommend treatment with dual anti-
platelet therapy (DAPT) to reduce the risks of major
adverse cardiac events (MACE) and stent thrombosis
(2); however, clinicians may be reluctant to treat AF
patients with concurrent indications for DAPT by us-
ing the combination of warfarin, aspirin, and clopi-
dogrel (triple therapy) due to the high bleeding risk
associated with this regimen (3,4).
Although previous studies have found that
bleeding risk is higher among patients receiving triple
therapy (4–6), some data also suggest a lower risk of
MACE among patients treated with triple therapy
relative to DAPT (7,8). Given the paucity of random-
ized data, studies have shown variability in antico-
agulant agent use according to the predicted risks of
stroke and bleeding in this patient population (8–11).
Therapeutic decisions for older patients with AF and
coronary artery disease may be especially chal-
lenging. Older patients in particular are at greater risk
for AF-related stroke and recurrent events after acute
MI but also have a higher risk for bleeding events (12).
Importantly, the older population has been excluded
from or underrepresented in clinical trials and,
therefore, remains understudied.
By linking data from the National Cardiovascular
Data Registry Acute Coronary Treatment and Inter-
vention Outcomes Network Registry–Get With the
Guidelines (ACTION Registry–GWTG) with Medicare
administrative claims, we had a unique opportunityClinical Research Institute (clinical trial steering committee), HMP Commun
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with AF undergoing PCI. We sought to: 1)
describe the patterns of use of discharge tri-
ple therapy versus DAPT in older MI patients
with AF treated by using PCI; 2) characterize
warfarin use patterns post-discharge; and 3)
compare the safety and effectiveness of triple
therapy versus DAPT.
METHODS
DATA SOURCES. Clinical and procedural
data for our study were obtained from the
ACTION Registry–GWTG, a national quality
improvement registry capturing data on
consecutive MI patients treated at >500
hospitals in the United States; this registry
has been described previously (13). Because
patient information was collected without
unique patient identiﬁers, we used indirect
identiﬁers in combination (date of birth, sex,
hospital identiﬁcation, date of admission,
and date of discharge) to link patients
$65 years of age in the ACTION Registry–GWTG with
Medicare claims data (methods previously described)
(14). The linked data for our analysis were available
from January 1, 2007, through December 31, 2010. We
examined longitudinal outcomes by using Medicare
Part A inpatient administrative data, and information
regarding post-discharge warfarin and P2Y12 receptor
inhibitor use was obtained from Medicare Part D data.
Warfarin was the only anticoagulant agent available
for clinical use in the United States during this time
period.
STUDY POPULATION. Among 123,349 patients $65
years of age at 683 sites identiﬁed in the ACTION
Registry–GWTG during our study period, 64.7%
(79,750 patients from 502 sites) were linked to Cen-
ters for Medicare & Medicaid Services data (Figure 1).
In this linked database, there were 6,098 patients
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FIGURE 1 Study Population
Patients in ACTION Registry-GWTG ≥ 65 years old with Medicare insurance (n=123,349 patients; 683 sites)
Medicare-insured patients ≥ 65 years old in ACTION Registry-GWTG linked to CMS (n= 79,750 patients; 502 sites)
Excluded (n=955)
Excluded (n=184)
Final analysis population (n=4,959 patients; 400 sites)
Documented contraindication to warfarin
(n=103)
Missing data on discharge warfarin use (n=16)
Non-index admissions for patients with
multiple records (n=65)
AMI patients with AF or atrial flutter with stent placement discharged home on DAPT (n=5,143)
Died during index hospitalization (n=374)
Transferred out to acute care facilities (n=63)
Left against medical advice or discharged on
comfort measures or to hospice (n=74)
Not prescribed aspirin and thienopyridine at
discharge (n=444)
Patients with AF and AMI in ACTION Registry-GWTG linked to CMS undergoing PCI with stent
placement (n=6,098 patients; 405 sites)
Flow diagram of the study cohort, from initial study population through exclusions. ACTION Registry–GWTG ¼ Acute Coronary Treatment and
Intervention Outcomes Network Registry–Get With the Guidelines; AF ¼ atrial ﬁbrillation; AMI ¼ acute myocardial infarction; CMS ¼ Centers
for Medicare & Medicaid Services; DAPT ¼ dual antiplatelet therapy; PCI ¼ percutaneous coronary intervention.
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618fee-for-service during the index discharge month,
who had a history of AF or atrial ﬂutter, and who
underwent in-hospital PCI with stent placement at 1
of 405 hospitals in the ACTION Registry–GWTG dur-
ing this study period. History of AF or atrial ﬂutter
was considered to be present if indicated as occurring
during the 2 weeks before the MI admission on the
ACTION Registry–GWTG data collection form or if the
International Classiﬁcation of Diseases-Ninth Revi-
sion code 427.3x appeared in any inpatient or
outpatient encounter billing record within the year
before the index MI hospitalization. In-hospital PCI
and stent use were determined from the ACTION
Registry–GWTG data collection form. We excluded
patients who died during the index hospitalization
(n ¼ 374), were transferred out to another acute care
hospital (n ¼ 63), and who left against medical advice
or were discharged on comfort measures or to hospice
(n ¼ 74). Also excluded were patients who were not
discharged on both aspirin and a P2Y12 antagonist
(clopidogrel, prasugrel, or ticlopidine; n ¼ 444), pa-
tients with a documented contraindication to
warfarin (n ¼ 103), patients with missing data on
discharge warfarin use (n ¼ 16), and nonindex ad-
missions for patients with multiple records (n ¼ 65).
Our ﬁnal analysis population consisted of 4,959patients treated at 400 sites. A breakdown of the data
source used to identify AF patients is shown in the
Online Appendix.
OUTCOMES AND DEFINITIONS. The primary effec-
tiveness outcome for our study was MACE at 2 years,
deﬁned as death or readmission for MI or stroke
(ischemic and hemorrhagic). Secondary effectiveness
outcomes included individual components of the
composite MACE outcome, as well as ischemic stroke
alone. We also examined bleeding readmission within
2 years after the index hospitalization as our primary
safety endpoint, as well as readmissions involving
intracranial hemorrhage. Outcomes were identiﬁed
by using International Classiﬁcation of Diseases-
Ninth Revision codes (Online Appendix) from Medi-
care inpatient claims data.
Patients were classiﬁed according to stroke risk
by using the CHADS2 (congestive heart failure, hy-
pertension, age $75 years, diabetes, prior stroke or
transient ischemic attack) risk score (15). CHADS2
scores were calculated by assigning 1 point each for
history of congestive heart failure, hypertension,
age $75 years, or diabetes mellitus, and 2 points for
history of stroke or transient ischemic attack. To
determine patient risk for bleeding, we calculated
the ATRIA (Anticoagulation and Risk Factors in
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619Atrial Fibrillation) risk score (16). ATRIA scores were
summed by assigning 3 points each for anemia
(hemoglobin <13 g/dl in men, <12 g/dl in women) or
severe renal disease (glomerular ﬁltration rate<30ml/
min or dialysis dependent), 2 points for age $75 years,
and 1 point each for hypertension or prior bleeding.
An ATRIA score >3 was considered high bleeding risk.
As a sensitivity analysis, post-discharge warfarin
and P2Y12 inhibitor prescription ﬁll information was
obtained from a Medicare Part D prescription claims
database (n ¼ 1,591). We then examined medication
persistence at 90 days after discharge from the index
MI hospitalization, deﬁned as continuation of the
medication prescribed at discharge without a gap in
ﬁlling >60 days (17). We also examined warfarin
initiation post-discharge by determining time to ﬁrst
warfarin prescription ﬁll post-discharge.
STATISTICAL ANALYSIS. Baseline clinical and pro-
cedural characteristics were described according to
discharge on DAPT versus triple therapy. Continuous
and categorical variables were presented by using
medians with interquartile ranges and proportions,
respectively, and compared by using respective Wil-
coxon rank-sum and chi-square tests. Kaplan-Meier
estimates of all-cause mortality and MACE outcomes
were reported, and readmission outcomes were re-
ported by using the cumulative incidence function to
account for the competing risk of death. Follow-up
for all outcomes was started at the time of discharge
from the index hospitalization. Inverse probability
weighting was used to account for confounding by
observed covariates, and the relationship between
discharge therapy and outcomes was assessed as
intention-to-treat. Propensity scores were estimated
by using logistic regression with triple therapy versus
DAPT as the outcome to determine the probability of
each patient undergoing the treatment he or she
received conditional on observed covariates. The in-
verse of this probability was then assigned as each
patient’s “weight.” Unadjusted and adjusted Cox
proportional hazard models were ﬁt for each outcome
of interest: unadjusted models included discharge
therapy as the sole variable, and weights were then
applied in adjusted models. The proportional hazards
assumption was met for all models, and covariates
were adequately balanced after propensity score
weighting (Online Appendix). Hazard ratios (HRs) for
triple therapy versus DAPT and corresponding 95%
conﬁdence intervals (CIs) were reported.
The following variables were used in the pro-
pensity models (these covariates were selected on the
basis of clinical judgment, as well as signiﬁcant dif-
ferences observed in univariate comparisons): age,
sex, body mass index, hypertension, dyslipidemia,diabetes, peripheral artery disease, prior MI, prior
PCI, prior coronary artery bypass grafting (CABG),
prior heart failure, prior stroke, prior bleeding within
1 year, home medications (i.e., aspirin, beta-blocker,
angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker, statin), MI type (ST-segment
elevation myocardial infarction [STEMI] vs. non–ST-
segment elevation myocardial infarction [NSTEMI]),
signs and symptoms of heart failure at presentation or
in-hospital, left ventricular ejection fraction (i.e.,
>40%, #40%, not evaluated), baseline hemoglobin,
baseline creatinine, arrival-to-cardiac catheterization
time #48 h, multivessel disease, drug-eluting stent
(DES) versus bare-metal stent use, discharge medi-
cations (i.e., angiotensin-converting enzyme inhibi-
tor or angiotensin receptor blocker, statin), hospital
region and teaching status, and in-hospital major
bleeding. In-hospital major bleeding is deﬁned by
the ACTION Registry–GWTG as an absolute hemo-
globin decrease of $4 g/dl, intracranial hemorrhage,
documented or suspected retroperitoneal bleed, any
red blood cell transfusion with baseline hemoglobin
$9 g/dl, or transfusion with baseline hemoglobin
<9 g/dl with a suspected bleeding event. Only pre-
operative bleeding events in CABG patients were
included. All variables had a missing rate <1%. For all
modeling, missing categorical variables were imputed
to the most frequent level, and missing continuous
variables were imputed to the median.
Several secondary analyses were conducted. First,
we assessed for differences in the relationship
between discharge therapy and outcomes in the
following subgroups of interest: age $75 years
versus <75 years, female versus male patients, high
versus low CHADS2 risk score, high versus low ATRIA
bleeding risk score, DES versus bare-metal stent use,
and MI type (NSTEMI versus STEMI). For each sub-
group, the propensity score model was allowed to
include interactions with the subgroup of interest,
such that balance would be preserved within each
subgroup. The subgroup variable and interaction
term were then added into the Cox models. As a
sensitivity study, a landmark analysis was performed
examining the associations between 90-day treat-
ment status and subsequent MACE and bleeding
outcomes among patients enrolled in Medicare Part D
at 90 days post-discharge. We compared outcomes
among patients discharged on warfarin who were
persistently on warfarin therapy at 90 days post-
discharge versus those not discharged on warfarin
who did not ﬁll a warfarin prescription within 90 days
post-discharge.
The Duke University Medical Center Institutional
Review Board granted a waiver of the informed
TABLE 1 Patient, In-Hospital, and Discharge Treatment Characteristics According
to Discharge Warfarin Use
DAPT
(n ¼ 3,589)
Triple Therapy*
(n ¼ 1,370) p Value
Patient features
Age, yrs 78.0 (72.0–84.0) 77.0 (72.0–82.0) <0.01
Female 1,602 (44.6) 505 (36.9) <0.01
Body mass index, kg/m2 26.6 (23.6–30.5) 27.7 (24.6–31.6) <0.01
Hypertension 2,911 (81.1) 1,145 (83.6) 0.04
Dyslipidemia 2,226 (62.0) 922 (67.3) <0.01
Diabetes 1,075 (30.0) 486 (35.5) <0.01
Prior MI 991 (27.6) 431 (31.5) <0.01
Prior HF 606 (16.9) 337 (24.6) <0.01
Prior CABG 730 (20.3) 362 (26.4) <0.01
Prior PCI 1,014 (28.3) 424 (31.0) <0.01
AF/ﬂutter in previous 2 weeks 1,014 (39.7) 586 (60.8) <0.01
Prior stroke 369 (10.3) 175 (12.8) 0.01
Peripheral arterial disease 466 (13.0) 211 (15.4) 0.03
CHADS2 score <0.01
0 186 (5.2) 39 (2.9)
1 733 (20.4) 244 (17.8)
2 1,201 (33.5) 444 (32.4)
3 899 (25.1) 362 (26.4)
4 372 (10.4) 189 (13.8)
5 112 (3.1) 66 (4.8)
6 52 (1.5) 22 (1.6)
ATRIA score >3 1,286 (35.8) 457 (33.4) 0.10
Bleeding admission in prior year 127 (3.5) 41 (3.0) 0.34
Home antithrombotic therapy
Aspirin 1,948 (54.3) 664 (48.4) <0.01
Clopidogrel 686 (19.1) 173 (12.6) <0.01
Prasugrel 3 (0.1) 3 (0.3) 0.21
Warfarin 276 (7.7) 851 (62.1) <0.01
In-hospital features
NSTEMI (vs. STEMI) 2,014 (56.1) 862 (62.9) <0.01
Baseline hemoglobin, g/dl 13.4 (12.1–14.6) 13.5 (12.3–14.7) <0.01
Baseline creatinine, mg/dl 1.1 (0.9–1.4) 1.2 (0.9–1.4) 0.05
LVEF >40% 2482 (74.3) 839 (65.6) <0.01
Time to catheterization, h 5.8 (1.0–32.0) 14.9 (1.1–46.1) <0.01
Multivessel disease 2,483 (69.7) 953 (70.03) 0.92
DES use (STEMI) 640 (47.8) 202 (46.4) 0.62
DES use (NSTEMI) 1,233 (61.2) 458 (53.1) <0.01
Procedural antithrombotic therapy
Unfractionated heparin 2,484 (69.6) 923 (68.5) 0.47
Low-molecular-weight heparin 1,068 (29.9) 364 (27.0) 0.05
Glycoprotein IIb/IIIa inhibitor 1,727 (49.9) 528 (40.2) <0.01
Bivalirudin 1,214 (34.0) 513 (38.1) <0.01
CABG 35 (1.0) 4 (0.3) 0.02
Major bleeding event 569 (15.9) 174 (12.7) <0.01
Discharge P2Y12 inhibitor
Clopidogrel 3,490 (97.7) 1,346 (98.8) 0.01
Prasugrel 89 (3.5) 19 (2.0) 0.02
Ticlopidine 10 (0.5) 5 (0.5) 0.86
Categorical variables presented as n (%) and continuous variables presented as median (25th to 75th percentiles).
*Triple therapy indicates warfarin, aspirin, and P2Y12 inhibitor.
AF ¼ atrial ﬁbrillation; ATRIA ¼ Anticoagulation and Risk Factors in Atrial Fibrillation; CABG ¼ coronary artery
bypass grafting; CHADS2 ¼ congestive heart failure, hypertension, age$75 years, diabetes, prior stroke/transient
ischemic attack; DAPT ¼ dual antiplatelet therapy; DES ¼ drug-eluting stent(s); HF ¼ heart failure; LVEF ¼ left
ventricular ejection fraction; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; PCI ¼ percutaneous coronary intervention; RBC ¼ red blood cell; STEMI ¼ ST-segment elevation
myocardial infarction.
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620consent and authorization for this study, and all
analyses were conducted by the Duke Clinical
Research Institute.
RESULTS
PATIENT AND IN-HOSPITAL CHARACTERISTICS AMONG
DAPT VERSUS TRIPLE THERAPY GROUPS. Among 4,959
MI patients presenting with a history of AF who were
treated with PCI, 27.6% (n ¼ 1,370) were discharged
on triple therapy, and 72.4% (n ¼ 3,589) were dis-
charged on DAPT (Table 1). Compared with patients
prescribed DAPT at discharge, those receiving triple
therapy were more often male and more frequently
had a history of PCI or CABG, prior stroke, and recent
AF or atrial ﬂutter. Patients discharged on triple
therapy were frequently already on warfarin before
admission, whereas those discharged on DAPT were
more likely to have had an in-hospital major bleeding
event. Use of triple therapy increased with higher
predicted stroke risk (p for trend < 0.0001) but was
not associated with predicted bleeding risk (p for
trend ¼ 0.18) (Figure 2). Patients in the triple therapy
group also more often presented with NSTEMI than
STEMI and more often had a left ventricular ejection
fraction #40%. There was greater use of glycoprotein
IIb/IIIa inhibitors among patients discharged on
DAPT, whereas patients in the triple therapy group
more often received bivalirudin during their PCI. Pa-
tients prescribed triple therapy who underwent PCI
for NSTEMI were less likely to undergo DES implan-
tation, whereas DES use for primary PCI among
STEMI patients was similar between the DAPT and
triple therapy groups.
CLINICAL OUTCOMES ACCORDING TO DISCHARGE
ANTITHROMBOTIC REGIMEN. Clinical outcomes were
examined according to discharge prescription of
triple therapy versus DAPT (Figure 3). Unadjusted
cumulative incidence rates of 2-year post-discharge
MACE between triple therapy and DAPT groups
were similar (32.6% vs. 32.7%; p ¼ 0.99). Unadjusted
cumulative incidence rates of the individual MACE
component endpoints were also similar between
patients discharged on triple therapy versus DAPT:
all-cause mortality (23.8% vs. 24.8%; p ¼ 0.70), MI
readmission (8.5% vs. 8.1%; p ¼ 0.54), and stroke
readmission (4.7% vs. 5.3%; p ¼ 0.23). The unadjusted
cumulative incidence of ischemic stroke was lower
for patients discharged on triple therapy versus DAPT
(3.2% vs. 4.7%; p ¼ 0.02). After adjustment for pa-
tient, treatment, and hospital characteristics, there
was no association of triple therapy with 2-year MACE
(adjusted HR: 0.99 [95% CI: 0.86 to 1.16]; p ¼ 0.94),
all-cause mortality (adjusted HR: 0.98 [95% CI: 0.83
FIGURE 2 Warfarin Use According to Risk of
Stroke and Bleeding
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using the CHADS2 (congestive heart failure, hypertension,
age $75 years, diabetes, prior stroke or transient ischemic
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(Anticoagulation and Risk Factors in Atrial Fibrillation) score.
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621to 1.16]; p ¼ 0.82), MI readmission (adjusted HR: 1.03
[95% CI: 0.79 to 1.33]; p ¼ 0.83), or stroke readmission
(adjusted HR: 0.85 [95% CI: 0.58 to 1.23]; p ¼ 0.38).
The adjusted HR for ischemic stroke was lower at 0.66
with triple therapy compared with DAPT; however,
this comparison remained nonstatistically signiﬁcant
(95% CI: 0.41 to 1.06; p ¼ 0.09).
The cumulative incidence of bleeding requiring
hospitalization within 2 years post-discharge was
signiﬁcantly higher for patients discharged on triple
therapy compared with DAPT (17.6% vs. 11.0%;
p < 0.0001), with curves diverging early after dis-
charge (Figure 4A). This association persisted after
adjustment for case-mix, treatment, and hospital
features (adjusted HR: 1.61 [95% CI: 1.31 to 1.97];
p < 0.0001). Unadjusted cumulative incidence
of intracranial hemorrhage was higher for patientstreated with triple therapy versus DAPT (3.4% vs.
1.5%; p < 0.001) (Figure 4B). After adjustment, triple
therapy remained signiﬁcantly associated with in-
tracranial hemorrhage (adjusted HR: 2.04 [95% CI:
1.25 to 3.34]; p < 0.01).
SECONDARY ANALYSES. Several subgroup analyses
were performed. After adjustment, the association of
triple therapy with risk of 2-year MACE was similar
between older ($75 years) versus younger patients,
men versus women, patients with high (CHADS2 score
cutoffs of >2 and $4) versus low predicted stroke
risk, patients with shorter versus longer duration of
AF, patients treated with DES versus bare-metal
stent, and patients presenting with NSTEMI versus
STEMI (p for interaction >0.05 for all) (Figure 5A).
Among these same subgroups, results were also
consistent when examining triple therapy and risk of
2-year bleeding readmissions (adjusted p for interac-
tion >0.05) (Figure 5B).
A total of 1,591 patients in our study had Medicare
Part D prescription coverage before discharge. Among
this cohort, 27.8% (n ¼ 442) were discharged on
warfarin, and 72.2% (n ¼ 1,149) were discharged on
DAPT only. Post-discharge antithrombotic therapy
use was examined (Table 2). Within 90 days post-
discharge, the rates of warfarin persistence among
patients discharged on warfarin was 93.2% (n ¼ 412),
and P2Y12 inhibitor persistence among patients dis-
charged on DAPT was 94.7% (n ¼ 1,088). Among pa-
tients not discharged on warfarin, 11.4% (n ¼ 232) had
ﬁlled a warfarin prescription within 90 days of
discharge. Of the 425 patients with a CHADS2 score >2
who were not discharged on warfarin, 12.7% had ﬁlled
a warfarin prescription within 90 days of discharge. In
a landmark analysis starting 90 days post-discharge,
we found that patients discharged on warfarin who
were persistently taking warfarin at that time had a
similar 2-year risk of MACE (adjusted HR: 0.96 [95%
CI: 0.67 to 1.36]; p ¼ 0.81) and a trend for higher risk
of bleeding (adjusted HR: 1.50 [95% CI: 0.92 to 2.46];
p ¼ 0.10) compared with patients not discharged on
warfarin who had not ﬁlled a warfarin prescription
during that time.
DISCUSSION
This is one of the largest studies of antithrombotic
treatment and outcomes of older acute MI patients
with history of AF who were treated with PCI. Overall,
we found that about one-fourth of patients were
discharged on triple therapy. Use of triple therapy
versus DAPT increased with predicted stroke risk but
not with bleeding risk. Compared with DAPT, the use
of triple therapy was not associated with a lower
FIGURE 3 MACE Outcomes According to Use of Triple Therapy Versus DAPT
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FIGURE 4 Bleeding Outcomes According to Triple Therapy Versus DAPT
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6232-year risk of mortality or MACE but was associated
with a signiﬁcantly higher early and long-term risk of
bleeding, including intracranial hemorrhage (Central
Illustration). These associations were robust among
various patient subgroups assessed according to age,
sex, predicted stroke and bleeding risk groups, stent
type, and MI type.
Deﬁning the optimal antithrombotic treatment
strategy for MI patients with history of AF who have
been treated with PCI has been a conundrum given the
limited randomized trial evidence and the safety
concerns observed with triple therapy in this patient
population. To date, however, much of the available
data have come from observational single-center
studies and have had conﬂicting ﬁndings with regard
to any beneﬁt of triple therapy on MACE (6,7,18–22).
For example, a recent report investigating 1,648 pa-
tients with AF undergoing stenting for NSTEMI found
that triple therapy was not associated with a risk of
stroke or bleeding (22). In a Danish study of 12,165 AF
patients with either MI or PCI, DAPT and individual
combinations of oral anticoagulation plus clopidogrel
or aspirin were not associated with increased coronary
events compared with triple therapy; nevertheless,
DAPT was associated with increased all-cause mor-
tality and higher risk of ischemic stroke. Bleeding
rates with oral anticoagulation plus clopidogrel were
similar to those with triple therapy but lower for oral
anticoagulation plus aspirin or DAPT (20).
Our study adds to the existing literature in several
ways. First, we used national registry data from 2007
to 2010 from >400 U.S. hospitals to identify a large
cohort of MI patients with a history of AF who un-
derwent stent implantation; therefore, our study
population had clinical indications for both dual
antiplatelet and anticoagulant therapy. Second, we
focused on a growing population of older patients
who are at highest risk of thrombotic events (and
consequently might beneﬁt the most from triple
therapy) but who are also at high risk for bleeding.
This combination of a larger sample size and a
higher risk population permitted the statistical
power to assess the relationship between antith-
rombotic therapy selection and post-discharge out-
comes. Third, we had access to detailed clinical
information, as well as in-hospital treatments and
events captured in the ACTION Registry–GWTG, and
we were able to include these variables in robustly
risk-adjusted models. Finally, the use of Medicare
Part D data to examine post-discharge warfarin per-
sistence or initiation added insight when explaining
our ﬁndings.
In patients with an indication for anticoagulation
undergoing PCI with stenting or presenting with MI,current practice guidelines recommend use of triple
therapy for as short a time as possible (Level of Evi-
dence: C) but also advocate careful consideration of
stroke, thrombosis, and bleeding risk when making
treatment decisions (12,23). We found that 27.6% of
older MI patients with a history of AF treated with
PCI were discharged on triple therapy. This propor-
tion increased with the estimated stroke risk and did
not vary with the predicted bleeding risk, lending
insight into how U.S. providers decide between triple
therapy versus DAPT for these patients. In addition,
we observed high rates of warfarin persistence at
3 months post-MI among patients discharged on
triple therapy. Conversely, w1 in 9 patients not
FIGURE 5 MACE and Bleeding Outcomes Among Selected Subgroups
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Shown in the forest plot are outcomes for: (A)MACE; and (B) bleeding readmission comparing triple therapy versus DAPT among patients according to age, sex, CHADS2
score, ATRIA score, atrial ﬁbrillation/ﬂutter duration, stent type, and MI type. BMS ¼ bare-metal stent(s); CI ¼ conﬁdence interval; DES ¼ drug-eluting stent(s);
HR ¼ hazard ratio; NSTEMI ¼ non–ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in
Figures 1 to 4.
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624discharged on warfarin were started on warfarin in
the next 3 months. Some of these delayed initiations
may be due to completion of the P2Y12 inhibitor
treatment course, resolution of in-hospital bleeding
events, recurrence of AF events, or perhaps deferral
of treatment decisions to an outpatient care provider.
Further investigation may help to clarify the beneﬁts
and risk of upfront versus delayed anticoagulation in
these PCI-treated patients with AF.
Our study suggests that, compared with DAPT,
triple therapy use is not associated with lower MACE
risk among older acute MI patients with a history ofTABLE 2 Post-Discharge Antithrombotic Medication Persistence
DAPT
Evaluable (n)
% (n) Remaining
on P2Y12 Inhibitor N
3 months 1,149 94.7% (1,088)
6 months 1,013 94.4% (956)
12 months 722 73.4% (530)
Abbreviation as in Table 1.AF undergoing coronary stenting. The 90-day land-
mark analysis conﬁrms these ﬁndings among patients
who remain on warfarin therapy for at least 90 days
versus those who were not anticoagulated. Further-
more, we tested for interactions among multiple
subgroups and found no evidence of any association
of triple therapy with outcomes. There was, however,
a nonsigniﬁcant trend for lower risk of ischemic
stroke associated with triple therapy, an endpoint for
which warfarin might be expected to have the great-
est potential beneﬁt. These ﬁndings differ from
a previous report of increased mortality amongTriple Therapy
o. Evaluable
% (No.) Remaining on
P2Y12 Inhibitor
% (n) Remaining
on Warfarin
442 95.9% (424) 93.4% (412)
368 94.6% (348) 91.8% (338)
270 63.7% (172) 57.4% (155)
CENTRAL ILLUSTRATION Outcomes According to Triple Therapy Versus DAPT
Hess, C.N. et al. J Am Coll Cardiol. 2015; 66(6):616–27.
The Kaplan-Meier curves demonstrate major adverse cardiac events (MACE); and bleeding readmission for patients on triple therapy versus dual antiplatelet therapy
(DAPT). MI ¼ myocardial infarction.
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625patients taking DAPT versus triple therapy (20). In
another study by the same investigators, the authors
found an immediate risk of bleeding after MI/PCI that
was highest with triple therapy compared with other
antithrombotic regimens (4). They also found that the
higher risk of triple therapy–associated bleeding
persisted over the next year. We observed similar
early divergence of our bleeding curves with
continued separation over the study period, indi-
cating persistently increased bleeding risk with triple
therapy versus DAPT. In addition, we found that tri-
ple therapy compared with DAPT was associated with
a signiﬁcantly increased risk of intracranial hemor-
rhage. Taken together, these studies suggest that we
need to carefully consider the risk/beneﬁt ratio of
immediate triple therapy use among older patients
with AF and acute MI treated with PCI.
Several lines of investigation may help to assess
alternatives to triple therapy for these types of pa-
tients. The MUSICA-2 (Anticoagulation in Stent
Intervention; NCT01141153) trial is currently rando-
mizing lower risk AF patients undergoing stenting to
triple therapy or DAPT, and the ongoing ISAR-Triple
(Triple Therapy in Patients on Oral Anticoagulation
after Drug-Eluting Stent Implantation; NCT00776633)trial is studying AF patients undergoing DES place-
ment treated with triple therapy for 6 weeks versus
6 months. The WOEST (What Is the Optimal Anti-
platelet and Anticoagulant Therapy in Patients with
Oral Anticoagulation and Coronary Stenting) trial
randomized patients taking oral anticoagulant agents
undergoing PCI to receive additional clopidogrel or
clopidogrel plus aspirin (24). The investigators found
that compared with triple therapy, clopidogrel plus
warfarin reduced bleeding complications but did not
increase thrombotic events. Although we examined
triple therapy versus DAPT, the WOEST results sug-
gest that use of warfarin plus clopidogrel as an
alternative to triple therapy could be further investi-
gated in our study population. Finally, how novel
oral anticoagulant agents used for thromboprophy-
laxis in AF patients (e.g., dabigatran, rivaroxaban,
apixiban) interact with antiplatelet therapy is of great
interest. Available data thus far demonstrate
increased bleeding with these drugs when used in
combination with antiplatelet therapy after MI
(25,26), but these agents may provide an advantage
when combined with a single antiplatelet agent,
potentially including an antiplatelet more potent
than clopidogrel (e.g., prasugrel, ticagrelor). An
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Approximately one-fourth of older patients with AF
who undergo coronary stenting after acute MI in
the United States are discharged on DAPT plus an
anticoagulant agent (triple therapy). Compared with
those taking DAPT alone, patients on triple therapy
had similar rates of MACE but experienced signiﬁ-
cantly greater risk of bleeding.
TRANSLATIONAL OUTLOOK: Prospective studies
are needed to compare the risks and beneﬁts of various
combinations of antithrombotic therapy, including
target-speciﬁc oral anticoagulant agents, in patients
with AF undergoing coronary stenting after acute MI.
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626ongoing randomized trial studying combinations of
rivaroxaban, warfarin, and DAPT in AF patients un-
dergoing PCI will add important insight to the ﬁeld
(PIONEER AF-PCI [A Study Exploring Two Strategies
of Rivaroxaban and One of Oral Vitamin K Antagonist
in Patients With Atrial Fibrillation Who Undergo
Percutaneous Coronary Intervention]; NCT01830543);
a similar trial with dabigatran (REDUAL PCI [Eval-
uation of Dual Therapy with Dabigatran vs. Triple
Therapy with Warfarin in Patients with AF That
Undergo a PCI with Stenting]; NCT02164864) is
planned.
STUDY LIMITATIONS. First, although the method of AF
identiﬁcation by using Medicare and registry data has
been previously used (5,27), it has not been validated;
therefore, differences in the data source for AF diagnosis
between the triple therapy and DAPT groups could result
in bias. For example, the greater proportion of AF patients
identiﬁed by using ACTION Registry–GWTG data in the
triple groupmight reﬂectmore permanent AF and, hence,
provider decisions for oral anticoagulation in addition to
DAPT. This approach, using a 1-year period to identify
prior AF diagnoses, may also miss patients with more
remoteAFdiagnoses. Second,ourstudywasobservational
and subject to unmeasured confounders. We had no data
regarding provider rationale for treatment choices (e.g.,
timing, type, or duration of AF; patient bleeding risk;
upcoming invasive procedures); as a result, selection
bias may persist despite propensity adjustment. Third,
ourprimary analysiswason thebasis of intention-to-treat.
We observed signiﬁcant post-discharge treatment cross-
over in the subcohort of Medicare Part D enrollees, with a
large drop in the proportion of patients taking warfarin
between 6 and 12 months. Multiple factors, such as
uncaptured bleeding events, reassessment of fall risk in
this older population, medication discontinuation for
procedures, and difﬁculty with international normalized
ratio monitoring, might account for this decrease. Such
treatment crossover may mask potential associations
betweenwarfarin use and outcomes. Fourth, althoughwe
included bleeding events involving rehospitalization,
we were unable to assess bleeding of lesser severity that
may have required outpatient evaluation and treatment
or may have affected quality of life or medication adher-
ence. Fifth, the study was likely underpowered to detect
differences in stroke and did not have adequate sample
size to compare combinations of antithrombotic therapies
other than triple therapy versus DAPT (e.g., warfarin
plus clopidogrel or aspirin). Sixth, we could not assess
novel oral anticoagulant agents given the timing of
this dataset. Seventh, we could not use the HAS-BLED
(hypertension, abnormal renal/liver function, stroke,
bleeding history/predisposition, labile internationalnormalized ratio, and elderly) bleeding risk score (28),
which is currently cited in the European guidelines, or the
HEMORR2HAGES (hepatic or renal disease, ethanol
abuse, malignancy, older, reduced platelet count/func-
tion, hypertension, anemia, genetic factors, excessive fall
risk, and stroke) score (29), because we did not have all
the data necessary to calculate these scores. Finally, our
analysis focused on older patients, and our results may
not apply to younger, healthier populations.
CONCLUSIONS
Balancing the risks of thrombosis and bleeding for
acute MI patients with concurrent indications for
antiplatelet and anticoagulant therapy remains a
therapeutic challenge, especially for older patients.
We observed that approximately one-fourth of older
MI patients with a history of AF who are treated with
coronary stenting in the United States are discharged
on triple therapy. Use of triple therapy was associated
with predicted risk of stroke but not bleeding. With
regard to downstream outcomes, triple and DAPT
therapy had similar MACE rates, but those treated
with triple therapy had signiﬁcantly higher early and
long-term risk of bleeding, including intracranial
hemorrhage, even after risk adjustment.
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